Schedule

14:00 - 14:30
Life-threatening headache: Non-vascular aetiologies

14:30 - 14:40
Discussion

14:40 - 15:10
Life-threatening headache: Vascular aetiologies

15:10 - 15:20
Discussion

15:20 - 15:50
Brain health and headache: Life-sustaining interventions

15:50 - 16:00
Discussion

14:00 - 14:25
Why, how, and when to prescribe exercises for patients with headaches

14:25 - 14:30
Discussion

14:30 - 14:55
Physical activity for the prevention of headache disorders

14:55 - 15:00
Discussion

15:00 - 15:25
The rationale of diet regulation on headache management

15:25 - 15:30
Discussion

15:30 - 15:55
Relaxation techniques

15:55 - 16:00
Discussion

14:00 - 14:20
CRISTINA TASSORELLI

14:20 - 14:40
VOLODYMYR ROMANENKO

14:40 - 15:00
RASHMI HALKER SINGH

15:00 - 15:20
ESME EKIZO?LU

15:20 - 15:40
BRONWYN JENKINS

15:40 - 16:00
MARCIO NATTAN

14:00 - 14:30
Overview of peripheral interventional treatments for headaches: Techniques and efficacy

14:30 - 15:00
Expanding access to peripheral nerve blocks: Addressing challenges and solutions

15:00 - 15:30
Botulinum toxin injections for chronic headaches: Clinical evidence and access barriers

15:30 - 16:00
The role of sphenopalatine ganglion (SPG) block and trigger point injections in headache management: Current practices and future directions

14:00 - 14:20
Acetaminophen

14:20 - 14:40
NSAIDs

14:40 - 15:00
Triptans and ditans

15:00 - 15:20
CGRP inhibitors

15:20 - 15:40
Neurotoxins

15:40 - 16:00
Lidocaine

14:00 - 14:40
Classification research. How to do it and use it

14:40 - 15:00
Research basis of chapter 4 diagnoses and future possibilities

15:20 - 15:40
Research basis of chapter 3 and the future of headache classification

15:40 - 16:00
Discussion

16:30 - 16:55
Fundamentals of clinical trial design: Key concepts and methodologies

16:55 - 17:00
Discussion

17:00 - 17:25
Innovative approaches in clinical trials: Adaptive designs and their applications

17:25 - 17:30
Discussion

17:30 - 17:55
Patient-centred outcomes in headache clinical trials: Measuring what matters

17:55 - 18:00
Discussion

18:00 - 18:25
Biomarkers and endpoints in headache trials: Challenges and opportunities

18:25 - 18:30
Discussion

16:30 - 16:55
Genetic models of migraine and how they might impact the lives of patients

16:55 - 17:00
Discussion

17:00 - 17:25
Innovations in pre-clinical neuroimaging using multiphoton microscopy and transgenic mice

17:25 - 17:30
Discussion

17:30 - 17:55
Defining functional brain networks using electrophysiology

17:55 - 18:00
Discussion

18:00 - 18:25
Chemogenetic manipulation of neuronal activity using small molecule ligand to activate synthetic G protein-coupled receptors and designer receptors exclusively activated by designer drugs (DREADDs)

18:25 - 18:30
Discussion

16:30 - 16:50
FREDA DODD GLOVER

16:50 - 17:10
TAKAO TAKESHIMA

17:10 - 17:30
YONG GANG WANG

17:30 - 18:00
Discussion

16:30 - 17:00
Implementing peripheral interventional treatments in diverse healthcare settings: Strategies for success

17:00 - 17:30
Policy and advocacy for expanding access to headache interventional treatments: Overcoming barriers

17:30 - 18:00
Break

18:00 - 18:30
Model-based practical applications for attenders

16:30 - 16:50
Amitriptyline (TCA)

16:50 - 17:10
Propranolol (beta blockers)

17:10 - 17:30
Topamax (anticonvulsant)

17:30 - 18:30
Discussion

08:30 - 08:45
Unveiling PACAP's role in migraine: Evidence from human provocation studies

08:45 - 09:00
Decoding PACAP signalling: Splice variants, pathways, and designer drugs

09:00 - 09:15
Can PACAP activate meningeal nociceptors?

09:15 - 09:30
PACAP vs. CGRP: Unveiling migraine mechanisms through mouse models

09:30 - 09:45
Profiling non-responders and super-responders to anti-CGRP treatment

09:45 - 10:00
Clinical features and biomarkers predicting treatment response in migraine

10:00 - 10:15
Role of central sensitisation and interictal allodynia

10:15 - 10:30
Molecular biomarkers and migraine treatment response

09:00 - 09:17
Connecting emotions, brain, and behaviour with wearables in migraine and chronic pain patients

09:17 - 09:34
Patient data to give the right patient the right treatment at the right time

09:34 - 09:51
The implementation of AI in the migraine field – from neural networks to networked care

09:51 - 10:00
Discussion

10:00 - 10:15
Deciphering the mechanisms: Pathophysiology of migraine-related cognitive dysfunction

10:15 - 10:30
Cognitive impairments in primary and secondary headache disorders

10:30 - 10:45
Migraine and cognitive decline

10:45 - 11:00
Altered cognition-related brain activity and interactions with acute pain

13:00 - 13:15
Rare variants with large effects provide functional insights into the pathology of migraine subtype

13:15 - 13:30
Shared genetics and causal relationships between migraine and its comorbidities

13:30 - 13:45
Genetic susceptibility of migraine endophenotypes across ethnicities

13:45 - 14:00
Mapping out neurons that contribute to headache (USA)

13:00 - 13:15
Facial trigeminal autonomic cephalalgias (TACs)

13:15 - 13:30
Low face migraine

13:30 - 13:45
Facial tension type headache

13:45 - 14:00
Optimising combined treatment for migraine and temporomandibular disease.

13:00 - 13:15
The biology and genetics of childhood and adolescent migraine: Why the prevalence is similar in childhood but different in adolescence

13:15 - 13:30
Mitochondrial role in paediatric migraine pathophysiology

13:30 - 13:45
The role of sex hormones in migraine attack initiation: Can we explain onset of migraine attacks during puberty?

13:45 - 14:00
Impact of co-morbidity, resilience, and vulnerability on childhood and adolescent headaches

14:00 - 14:15
Migraine multidisciplinary approach in family medicine

14:15 - 14:30
Exclusion of important life-threatening causes of headache

14:30 - 14:45
Managing primary headache disorders in a primary headache care setting

14:45 - 15:00
Discussion

14:00 - 14:15
Migraine with and without aura are distinct disorders

14:15 - 14:30
CSD provides a common therapeutic target for widely prescribed migraine prophylactic drugs and neuromodulation devices

14:30 - 14:45
Brain imaging in migraine with and without aura: Similarities and differences

14:45 - 15:00
Discussion

14:00 - 14:15
Treating the attack during the prodromal phase: Gain or waste?

14:15 - 14:30
Early prevention: Disease prevention or prevention of disease progression?

14:30 - 14:45
What do the guidelines say?

14:45 - 15:00
Discussion

14:00 - 14:15
Metabolic perspectives in idiopathic intracranial hypertension

14:15 - 14:30
Novel therapeutic approaches and efficacy of epidural blood patching or surgery in spontaneous intracranial hypotension

14:30 - 14:45
Proposing management strategies tailored to addressing intracranial hypotension

14:45 - 15:00
Discussion

15:00 - 15:15
Sex differences in response to triptans

15:15 - 15:30
Pain behaviours to CGRP and other neuropeptides – sex differences?

15:30 - 15:45
Evaluation of outcomes of CGRP-targeting therapies for acute and preventive migraine treatment based on patient sex

15:45 - 16:00
Is there a gender difference in the response to onabotulinumtoxinA or CGRP inhibitors in chronic migraine?

16:15 - 16:30
Circadian features of headache disorders – can I explain why?

16:30 - 16:45
Genetics and chronobiology of cluster headache

16:45 - 17:00
Chronobiology of cluster headache attacks – my proposed explanation

17:00 - 17:15
Discussion

16:15 - 16:30
Global disparities in migraine care: A call for universal access to diagnosis and treatment

16:30 - 16:45
Regional variations in headache burden

16:45 - 17:00
Migraine service quality in the global perspective of Lifting The Burden

17:00 - 17:15
Discussion

16:15 - 16:30
Migraine – a borderland disease to epilepsy: Near it but not of it

16:30 - 16:45
Pathophysiology of ictal and post-ictal headache

16:45 - 17:00
Migraine and idiopathic epilepsies comorbidity

17:00 - 17:15
Migraine and epilepsy: From bench to bedside

16:15 - 16:30
Scientific rationale for polytherapy

16:30 - 16:45
Acute treatment of migraine: When one drug is not enough

16:45 - 17:00
Prophylactic treatment of migraine: When one drug is not enough

17:00 - 17:15
Experiences with dual therapy with onabotulinumtoxinA and CGRP antibodies: Real world evidence data

09:00 - 09:15
Understanding the pathogenesis of cluster headache in the CGRP era: Where are we?

09:15 - 09:30
Do pathophysiological differences exist between episodic and chronic cluster headache?

09:30 - 09:45
Clinical response prediction of approved anti-CGRP in the prevention of cluster headache and what is next

09:45 - 10:00
Discussion

09:00 - 09:15
Decoding the aura table: Unveiling visual disturbances and perception in migraine auras

09:15 - 09:30
Beyond the scan: Exploring neuroimaging and the quest for objective documentation of migraine aura phenomena

09:30 - 09:45
Initiation and propagation of spreading depolarisation: Considerations for migraine

09:45 - 10:00
Discussion

09:00 - 09:15
Update on pharmacological options currently available for the treatment of migraine in children and adolescents

09:15 - 09:30
Does controlling migraine improve interictal cognition in children and adolescents? Does more need to be done?

09:30 - 09:45
What are the key messages for the non-pharmacological approach of migraine in children and adolescents?

09:45 - 10:00
Discussion

09:00 - 09:15
Transcranial direct current stimulation (tDCS)

09:15 - 09:30
Transcranial magnetic stimulation (TMS)

09:30 - 09:45
Peripheral nerve stimulation

09:45 - 10:00
Discussion

14:30 - 14:45
VSS is a form of migraine aura–overlapping clinical features, neurophysiology, and neuroimaging

14:45 - 15:00
VSS is a distinct clinical entity: What we learned from neuro-ophthalmological and behavioural research

15:00 - 15:15
Visual snow vs. migraine aura

15:15 - 15:30
Debate summary and novel insights into the syndrome

14:30 - 14:45
Sex and hormonal influences on migraine pain – the science

14:45 - 15:00
Prescribing for pregnancy: Managing chronic headache and migraine

15:00 - 15:15
CGRP, onabotulinumtoxinA, and others. Are they safe?

15:15 - 15:30
Addressing migraine in the breastfeeding period: Practical approaches for primary care providers

14:30 - 14:45
Demystifying trigeminal neuropathic pain in the face and mouth - guidelines on diagnosis, treatment, and follow-up care

14:45 - 15:00
The science behind neuromodulation procedures for trigeminal neuralgia

15:00 - 15:10
The role of tumours in headaches and neuralgias – the perspective from neurosurgery

15:10 - 15:30
Discussion

14:30 - 14:45
Telemedicine as a solution for headaches in LMIC countries

14:45 - 15:00
Telemedicine in headache education

15:00 - 15:15
How can better education improve the management of headaches in LMIC countries

15:15 - 15:30
Discussion

16:00 - 16:20
Non-paralytic botulinum toxins for the treatment of headaches and pain

16:20 - 16:40
Anti-nociceptive activities of novel long-acting SNARE-inactivating biotherapeutics

16:40 - 17:00
Chimeric toxin-based therapeutics

17:00 - 17:15
Cracking the code: Inconsistencies and issues in assessing the migraine prodrome

17:15 - 17:30
Different kinds of migraine triggers are reported in different parts of the world

17:30 - 17:45
The hypothalamus: Conductor of the migraine prodrome

17:45 - 18:00
Is the hypothalamus to blame? Rethinking its role in the migraine prodrome